Exagen Q2 FY26 net loss narrows 28% to $3.2 million; revenue rises 16% to $19.9 million

Reuters2026/08/04 12:09

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Exagen posted Q2 revenue of $ USD 19.9 million, up 16% from Q2 2025, as it set record revenue and test volume.
GAAP net loss narrowed to $ USD 3.2 million; GAAP operating loss tightened to $ USD 1.7 million.
Non-GAAP adjusted EBITDA loss shrank to $ USD 114,000 from $ USD 1.7 million a year earlier.
Trailing-twelve-month average selling price rose 4% to $ USD 446 per test; AVISE CTD test volume climbed 11% year over year.
Raised full-year 2026 revenue guidance to $ USD 72 million-$ USD 75 million; ended the quarter with about $ USD 25 million in cash.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exagen Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001274737-26-000047), on August 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Exagen Q2 FY26 net loss narrows 28% to $3.2 million; revenue rises 16% to $19.9 million

You may also like

Crypto prices